MeSH term
Frequency | Condition_Probility | Animals | 19 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Cell Division | 6 | 0.0 |
Humans | 57 | 0.0 |
Mice | 12 | 0.0 |
*Protein-Tyrosine Kinase | 3 | 0.0 |
Research Support, Non-U.S. Gov't | 33 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 18 | 0.0 |
Female | 17 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Phosphorylation | 7 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 3 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Rats | 3 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Gene Frequency | 6 | 0.0 |
Genetics, Population | 4 | 1.0 |
*Tandem Repeat Sequences | 6 | 5.0 |
Alleles | 6 | 0.0 |
China/ethnology | 2 | 1.0 |
*Chromosome Mapping | 2 | 0.0 |
English Abstract | 4 | 0.0 |
Heterozygote | 2 | 0.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Cell Line | 9 | 0.0 |
Receptor, Insulin/*metabolism | 2 | 3.0 |
Tumor Cells, Cultured | 2 | 0.0 |
*Cell Transformation, Neoplastic | 3 | 0.0 |
Enzyme Activation | 3 | 0.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
Protein Transport | 2 | 0.0 |
Child | 4 | 0.0 |
*Chromosomes, Human, Pair 15 | 3 | 1.0 |
Genetic Markers | 5 | 0.0 |
Genotype | 4 | 0.0 |
Male | 18 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
*Microsatellite Repeats | 2 | 0.0 |
Forensic Medicine | 2 | 3.0 |
Adult | 11 | 0.0 |
Aged | 4 | 0.0 |
Blotting, Southern | 3 | 0.0 |
Loss of Heterozygosity | 2 | 0.0 |
Middle Aged | 6 | 0.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Polymerase Chain Reaction | 11 | 0.0 |
Proto-Oncogene Proteins/*genetics | 2 | 0.0 |
Binding Sites | 2 | 0.0 |
Mutagenesis | 2 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Base Sequence | 6 | 0.0 |
Comparative Study | 5 | 0.0 |
*Gene Frequency | 5 | 0.0 |
Microsatellite Repeats/*genetics | 3 | 1.0 |
Molecular Sequence Data | 8 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Species Specificity | 2 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Analysis of Variance | 2 | 0.0 |
Spinal Cord Injuries/*rehabilitation | 2 | 66.0 |
Case-Control Studies | 3 | 0.0 |
Risk Factors | 2 | 0.0 |
*Electric Stimulation | 2 | 28.0 |
Muscle Contraction/*physiology | 2 | 4.0 |
Muscle, Skeletal/*physiology | 2 | 2.0 |
Adolescent | 4 | 0.0 |
COS Cells | 2 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Protein Binding/drug effects | 2 | 0.0 |
Receptors, Interleukin-4 | 3 | 4.0 |
Signal Transduction | 2 | 0.0 |
Transfection | 3 | 0.0 |
Amino Acid Sequence | 5 | 0.0 |
Feasibility Studies | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
*Electric Stimulation Therapy | 3 | 13.0 |
Interleukin-4/metabolism | 2 | 2.0 |
Kinetics | 2 | 0.0 |
Phosphotyrosine | 2 | 0.0 |
Proto-Oncogene Proteins/isolation & purification/*metabolism | 2 | 13.0 |
Electric Stimulation | 2 | 0.0 |
Electromyography | 3 | 1.0 |
Biopsy | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 3 | 0.0 |
DNA/*genetics | 2 | 0.0 |
Germany | 2 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Turkey | 2 | 1.0 |
Continental Population Groups/*genetics | 2 | 4.0 |
Cercopithecus aethiops | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
*Proto-Oncogenes | 2 | 0.0 |
Time Factors | 3 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Cells, Cultured | 2 | 0.0 |
*Oncogenes | 3 | 0.0 |
*Orthotic Devices | 2 | 40.0 |
Forensic Medicine/methods | 2 | 5.0 |
*Alleles | 2 | 0.0 |
